NY-BREGAL-SAGEMOUNT
10.1.2023 09:01:39 CET | Business Wire | Press release
Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm, today announced a strategic growth investment in Enhesa (the “Company”), a leading provider of regulatory and sustainability intelligence worldwide. As part of the transaction, Sagemount will acquire ICG’s minority stake in Enhesa, with existing investor CGE Partners (“CGE”) retaining its majority stake in the Company. Financial terms of the transaction were not disclosed.
With its global headquarters in Brussels, Belgium and U.S. headquarters in Arlington, VA, Enhesa empowers multinational corporations worldwide to help create a more sustainable future by positively impacting the environment and ensuring the health and safety of their employees and customers. Bringing together some of the world’s most comprehensive data sets, AI-powered analytics, and renowned subject matter experts in the areas of global operations, product, and chemicals management compliance and sustainability, Enhesa provides actionable compliance intelligence in over 40 languages across more than 300 jurisdictions, supported by a team of over 100 in-house legal experts. Navigating the fast-changing regulatory landscape, Enhesa helps corporations meet their compliance and sustainability needs with confidence, now and in the future.
“We are thrilled to be partnering with Sagemount as we enter our next stage of growth,” said Peter Schramme, CEO of Enhesa. “With their and CGE’s support and deep industry expertise, we believe we are well-positioned to further invest in our current offerings as well as accelerate new content coverage, use cases, and customer verticals.”
“We see tremendous growth ahead for Enhesa as a result of the Company’s strong product-market fit and tangible customer ROI,” said Pavan Tripathi, Partner at Sagemount. “Enhesa has an impressive track record of consistently retaining and growing its customer relationships as well as expanding new content offerings and jurisdictional coverage through both organic and inorganic growth initiatives. We are excited to be working with Peter, the Enhesa team, and CGE.”
David Greenbaum, Vice President at Sagemount, added, “For enterprises that operate, manufacture, and sell globally, Enhesa is by far the leading third-party content provider, allowing companies to monitor relevant Environmental, Health, & Safety (“EHS”) and other regulations across the enterprise significantly faster and more accurately than internal teams or disparate, regional third-party content providers.”
"We have enjoyed a highly successful partnership with Enhesa since acquiring the Company in 2020. Under CGE’s ownership to date, Enhesa has meaningfully scaled its business, expanded its industry-leading regulatory compliance content set from EHS to also include Product Compliance and Sustainability Intelligence, and completed five strategic add-on acquisitions," CGE commented. "We look forward to continuing to support Enhesa in its next chapter of growth alongside Sagemount."
Sagemount’s investment was led by Pavan Tripathi, Sandeep Swaminathan, David Greenbaum, Harrison Boyajian, and Stephanie Li. Sagemount was advised by Raymond James and Goodwin Procter. Enhesa and CGE were advised by Houlihan Lokey and Travers Smith.
About Enhesa
Enhesa is the leading provider of regulatory and sustainability intelligence worldwide. Headquartered in Brussels, with offices in Washington, DC, Williamsport, PA, Toronto, the United Kingdom, Tokyo, Shanghai, and Portugal, Enhesa empowers multinational corporations worldwide to create a more sustainable future by positively impacting the environment and ensuring the health and safety of their employees and customers. Bringing together some of the world’s most comprehensive data sets, AI-powered analytics, and renowned subject matter experts in the areas of global operations, product, and chemicals management compliance and sustainability, Enhesa provides actionable compliance intelligence in over 40 languages across more than 300 jurisdictions. Navigating the fast-changing regulatory landscape, Enhesa helps corporations meet their compliance and sustainability needs with confidence, now and in the future. For more information on Enhesa, go to the firm's website at www.enhesa.com.
About Sagemount
Bregal Sagemount is a leading growth-focused private capital firm with more than $6.0 billion of capital raised. The firm provides flexible capital and strategic assistance to market-leading companies in high-growth sectors across a wide variety of transaction situations. Bregal Sagemount has invested in over 70 companies in a variety of sectors, including software, information / data services, financial technology & specialty finance, digital infrastructure, healthcare IT, and business & consumer services. The firm has offices in New York, Palo Alto, and Dallas. For more information, visit the Sagemount website: www.sagemount.com or follow us on LinkedIn.
About CGE
CGE Partners is a European mid-market investment fund. CGE invests in tech-enabled businesses facilitating the transition to a more digital, renewable, secure, and compliant future, providing capital and expertise to accelerate expansion in global markets. For more information, visit the CGE website: https://cge-partners.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005348/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom